High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release
Abstract
:1. Introduction
2. Materials and Methods
2.1. Plasmids, Antibodies, and Chemicals
2.2. Cell Culture and Transfection
2.3. Western Blotting Analysis
2.4. Virus Release Assays
2.5. Flow Cytometry
2.6. Immunofluorescence Microscopy
3. Results
3.1. Glycosylation of At Least One Asn Is Required for Tetherin Antiviral Activity
3.2. Tunicamycin Abrogates the Antiviral Activity of Tetherin
3.3. Lack of Virus Release Inhibition by N65,92A Tetherin is Linked to Impaired Cell Surface Expression
3.4. Complex-Type Glycosylation Is Dispensable for Tetherin Restriction of Virus Release
3.5. Complex-Type Glycosylation of Tetherin Is Not Required for Its Cell-Surface Expression
4. Discussion
Acknowledgments
Author Contributions
Conflicts of Interest
References
- Neil, S.J.; Zang, T.; Bieniasz, P.D. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008, 451, 425–430. [Google Scholar] [CrossRef] [PubMed]
- Van Damme, N.; Goff, D.; Katsura, C.; Jorgenson, R.L.; Mitchell, R.; Johnson, M.C.; Stephens, E.B.; Guatelli, J. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008, 3, 245–252. [Google Scholar] [CrossRef] [PubMed]
- Blasius, A.L.; Giurisato, E.; Cella, M.; Schreiber, R.D.; Shaw, A.S.; Colonna, M. Bone marrow stromal cell antigen 2 is a specific marker of type I IFN-producing cells in the naive mouse, but a promiscuous cell surface antigen following ifn stimulation. J. Immunol. 2006, 177, 3260–3265. [Google Scholar] [CrossRef] [PubMed]
- Cai, D.; Cao, J.; Li, Z.; Zheng, X.; Yao, Y.; Li, W.; Yuan, Z. Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer 2009, 9, 102. [Google Scholar] [CrossRef] [PubMed]
- Capurso, G.; Lattimore, S.; Crnogorac-Jurcevic, T.; Panzuto, F.; Milione, M.; Bhakta, V.; Campanini, N.; Swift, S.M.; Bordi, C.; Delle Fave, G.; et al. Gene expression profiles of progressive pancreatic endocrine tumours and their liver metastases reveal potential novel markers and therapeutic targets. Endocr. Relat. Cancer 2006, 13, 541–558. [Google Scholar] [CrossRef] [PubMed]
- Erikson, E.; Adam, T.; Schmidt, S.; Lehmann-Koch, J.; Over, B.; Goffinet, C.; Harter, C.; Bekeredjian-Ding, I.; Sertel, S.; Lasitschka, F.; et al. In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans. Proc. Natl. Acad. Sci. USA 2011, 108, 13688–13693. [Google Scholar] [CrossRef] [PubMed]
- Giese, S.; Marsh, M. Tetherin can restrict cell-free and cell-cell transmission of HIV from primary macrophages to t cells. PLoS Pathog. 2014, 10, e1004189. [Google Scholar] [CrossRef] [PubMed]
- Goto, T.; Kennel, S.J.; Abe, M.; Takishita, M.; Kosaka, M.; Solomon, A.; Saito, S. A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 1994, 84, 1922–1930. [Google Scholar] [PubMed]
- Grutzmann, R.; Boriss, H.; Ammerpohl, O.; Luttges, J.; Kalthoff, H.; Schackert, H.K.; Kloppel, G.; Saeger, H.D.; Pilarsky, C. Meta-analysis of microarray data on pancreatic cancer defines a set of commonly dysregulated genes. Oncogene 2005, 24, 5079–5088. [Google Scholar] [CrossRef] [PubMed]
- Ishikawa, J.; Kaisho, T.; Tomizawa, H.; Lee, B.O.; Kobune, Y.; Inazawa, J.; Oritani, K.; Itoh, M.; Ochi, T.; Ishihara, K.; et al. Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 1995, 26, 527–534. [Google Scholar] [CrossRef]
- Kawai, S.; Yoshimura, Y.; Iida, S.; Kinoshita, Y.; Koishihara, Y.; Ozaki, S.; Matsumoto, T.; Kosaka, M.; Yamada-Okabe, H. Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncol. Rep. 2006, 15, 361–367. [Google Scholar] [CrossRef] [PubMed]
- Kuhl, B.D.; Sloan, R.D.; Donahue, D.A.; Liang, C.; Wainberg, M.A. Vpu-mediated tetherin antagonism of ongoing HIV-1 infection in CD4(+) T-cells is not directly related to the extent of tetherin cell surface downmodulation. Virology 2011, 417, 353–361. [Google Scholar] [CrossRef] [PubMed]
- Walter-Yohrling, J.; Cao, X.; Callahan, M.; Weber, W.; Morgenbesser, S.; Madden, S.L.; Wang, C.; Teicher, B.A. Identification of genes expressed in malignant cells that promote invasion. Cancer Res. 2003, 63, 8939–8947. [Google Scholar] [PubMed]
- Kupzig, S.; Korolchuk, V.; Rollason, R.; Sugden, A.; Wilde, A.; Banting, G. BST-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 2003, 4, 694–709. [Google Scholar] [CrossRef] [PubMed]
- Perez-Caballero, D.; Zang, T.; Ebrahimi, A.; McNatt, M.W.; Gregory, D.A.; Johnson, M.C.; Bieniasz, P.D. Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 2009, 139, 499–511. [Google Scholar] [CrossRef] [PubMed]
- Tokarev, A.A.; Munguia, J.; Guatelli, J.C. Serine-threonine ubiquitination mediates downregulation of BST-2/tetherin and relief of restricted virion release by HIV-1 Vpu. J. Virol. 2011, 85, 51–63. [Google Scholar] [CrossRef] [PubMed]
- Galao, R.P.; Le Tortorec, A.; Pickering, S.; Kueck, T.; Neil, S.J. Innate sensing of HIV-1 assembly by tetherin induces NF-κb-dependent proinflammatory responses. Cell Host Microbe 2012, 12, 633–644. [Google Scholar] [CrossRef] [PubMed]
- Masuyama, N.; Kuronita, T.; Tanaka, R.; Muto, T.; Hirota, Y.; Takigawa, A.; Fujita, H.; Aso, Y.; Amano, J.; Tanaka, Y. HM1.24 is internalized from lipid rafts by clathrin-mediated endocytosis through interaction with α-adaptin. J. Biol. Chem. 2009, 284, 15927–15941. [Google Scholar] [CrossRef] [PubMed]
- Matsuda, A.; Suzuki, Y.; Honda, G.; Muramatsu, S.; Matsuzaki, O.; Nagano, Y.; Doi, T.; Shimotohno, K.; Harada, T.; Nishida, E.; et al. Large-scale identification and characterization of human genes that activate NF-κb and MAPK signaling pathways. Oncogene 2003, 22, 3307–3318. [Google Scholar] [CrossRef] [PubMed]
- Andrew, A.J.; Miyagi, E.; Kao, S.; Strebel, K. The formation of cysteine-linked dimers of BST-2/tetherin is important for inhibition of HIV-1 virus release but not for sensitivity to Vpu. Retrovirology 2009, 6, 80. [Google Scholar] [CrossRef] [PubMed]
- Du Pont, K.E.; McKenzie, A.M.; Kokhan, O.; Sumner, I.; Berndsen, C.E. The disulfide bonds within BST-2 enhance tensile strength during viral tethering. Biochemistry 2016, 55, 940–947. [Google Scholar] [CrossRef] [PubMed]
- Ohtomo, T.; Sugamata, Y.; Ozaki, Y.; Ono, K.; Yoshimura, Y.; Kawai, S.; Koishihara, Y.; Ozaki, S.; Kosaka, M.; Hirano, T.; et al. Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem. Biophys. Res. Commun. 1999, 258, 583–591. [Google Scholar] [CrossRef] [PubMed]
- Mahauad-Fernandez, W.D.; Okeoma, C.M. The role of BST-2/tetherin in host protection and disease manifestation. Immun. Inflamm. Dis. 2016, 4, 4–23. [Google Scholar] [CrossRef] [PubMed]
- Neil, S.J. The antiviral activities of tetherin. Curr. Top. Microbiol. Immunol. 2013, 371, 67–104. [Google Scholar] [PubMed]
- Sauter, D. Counteraction of the multifunctional restriction factor tetherin. Front. Microbiol. 2014, 5, 163. [Google Scholar] [CrossRef] [PubMed]
- Douglas, J.L.; Viswanathan, K.; McCarroll, M.N.; Gustin, J.K.; Fruh, K.; Moses, A.V. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/tetherin via a β TrCP-dependent mechanism. J. Virol. 2009, 83, 7931–7947. [Google Scholar] [CrossRef] [PubMed]
- Dube, M.; Roy, B.B.; Guiot-Guillain, P.; Binette, J.; Mercier, J.; Chiasson, A.; Cohen, E.A. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment. PLoS Pathog. 2010, 6, e1000856. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Goffinet, C.; Allespach, I.; Homann, S.; Tervo, H.M.; Habermann, A.; Rupp, D.; Oberbremer, L.; Kern, C.; Tibroni, N.; Welsch, S.; et al. Hiv-1 antagonism of CD317 is species specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 2009, 5, 285–297. [Google Scholar] [CrossRef] [PubMed]
- Gupta, R.K.; Mlcochova, P.; Pelchen-Matthews, A.; Petit, S.J.; Mattiuzzo, G.; Pillay, D.; Takeuchi, Y.; Marsh, M.; Towers, G.J. Simian immunodeficiency virus envelope glycoprotein counteracts tetherin/BST-2/CD317 by intracellular sequestration. Proc. Natl. Acad. Sci. USA 2009, 106, 20889–20894. [Google Scholar] [CrossRef] [PubMed]
- Iwabu, Y.; Fujita, H.; Kinomoto, M.; Kaneko, K.; Ishizaka, Y.; Tanaka, Y.; Sata, T.; Tokunaga, K. Hiv-1 accessory protein Vpu internalizes cell-surface BST-2/tetherin through transmembrane interactions leading to lysosomes. J. Biol. Chem. 2009, 284, 35060–35072. [Google Scholar] [CrossRef] [PubMed]
- Mangeat, B.; Gers-Huber, G.; Lehmann, M.; Zufferey, M.; Luban, J.; Piguet, V. HIV-1 Vpu neutralizes the antiviral factor tetherin/bst-2 by binding it and directing its β TrCP-dependent degradation. PLoS Pathog. 2009, 5, e1000574. [Google Scholar] [CrossRef] [PubMed]
- Mitchell, R.S.; Katsura, C.; Skasko, M.A.; Fitzpatrick, K.; Lau, D.; Ruiz, A.; Stephens, E.B.; Margottin-Goguet, F.; Benarous, R.; Guatelli, J.C. Vpu antagonizes BST-2-mediated restriction of HIV-1 release via β TrCP and endo-lysosomal trafficking. PLoS Pathog. 2009, 5, e1000450. [Google Scholar] [CrossRef] [PubMed]
- Tervo, H.M.; Homann, S.; Ambiel, I.; Fritz, J.V.; Fackler, O.T.; Keppler, O.T. β TrCP is dispensable for Vpu’s ability to overcome the CD317/tetherin-imposed restriction to HIV-1 release. Retrovirology 2011, 8, 9. [Google Scholar] [CrossRef] [PubMed]
- Waheed, A.A.; Kuruppu, N.D.; Felton, K.L.; D’Souza, D.; Freed, E.O. In cos cells Vpu can both stabilize tetherin expression and counteract its antiviral activity. PLoS ONE 2014, 9, e111628. [Google Scholar] [CrossRef] [PubMed]
- Dube, M.; Paquay, C.; Roy, B.B.; Bego, M.G.; Mercier, J.; Cohen, E.A. HIV-1 Vpu antagonizes BST-2 by interfering mainly with the trafficking of newly synthesized BST-2 to the cell surface. Traffic 2011, 12, 1714–1729. [Google Scholar] [CrossRef] [PubMed]
- Lewinski, M.K.; Jafari, M.; Zhang, H.; Opella, S.J.; Guatelli, J. Membrane anchoring by a C-terminal tryptophan enables HIV-1 Vpu to displace bone marrow stromal antigen 2 (BST2) from sites of viral assembly. J. Biol. Chem. 2015, 290, 10919–10933. [Google Scholar] [CrossRef] [PubMed]
- Miyagi, E.; Andrew, A.J.; Kao, S.; Strebel, K. Vpu enhances HIV-1 virus release in the absence of BST-2 cell surface down-modulation and intracellular depletion. Proc. Natl. Acad. Sci. USA 2009, 106, 2868–2873. [Google Scholar] [CrossRef] [PubMed]
- Schmidt, S.; Fritz, J.V.; Bitzegeio, J.; Fackler, O.T.; Keppler, O.T. HIV-1 Vpu blocks recycling and biosynthetic transport of the intrinsic immunity factor CD317/tetherin to overcome the virion release restriction. mBio 2011, 2, e00036-11. [Google Scholar] [CrossRef] [PubMed]
- Jia, B.; Serra-Moreno, R.; Neidermyer, W.; Rahmberg, A.; Mackey, J.; Fofana, I.B.; Johnson, W.E.; Westmoreland, S.; Evans, D.T. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2. PLoS Pathog. 2009, 5, e1000429. [Google Scholar] [CrossRef] [PubMed]
- McNatt, M.W.; Zang, T.; Hatziioannou, T.; Bartlett, M.; Fofana, I.B.; Johnson, W.E.; Neil, S.J.; Bieniasz, P.D. Species-specific activity of HIV-1 Vpu and positive selection of tetherin transmembrane domain variants. PLoS Pathog. 2009, 5, e1000300. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Rong, L.; Zhang, J.; Lu, J.; Pan, Q.; Lorgeoux, R.P.; Aloysius, C.; Guo, F.; Liu, S.L.; Wainberg, M.A.; Liang, C. The transmembrane domain of BST-2 determines its sensitivity to down-modulation by human immunodeficiency virus type 1 Vpu. J. Virol. 2009, 83, 7536–7546. [Google Scholar] [CrossRef] [PubMed]
- Sauter, D.; Schindler, M.; Specht, A.; Landford, W.N.; Munch, J.; Kim, K.A.; Votteler, J.; Schubert, U.; Bibollet-Ruche, F.; Keele, B.F.; et al. Tetherin-driven adaptation of Vpu and Nef function and the evolution of pandemic and nonpandemic HIV-1 strains. Cell Host Microbe 2009, 6, 409–421. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Gotz, N.; Sauter, D.; Usmani, S.M.; Fritz, J.V.; Goffinet, C.; Heigele, A.; Geyer, M.; Bibollet-Ruche, F.; Learn, G.H.; Fackler, O.T.; et al. Reacquisition of Nef-mediated tetherin antagonism in a single in vivo passage of HIV-1 through its original chimpanzee host. Cell Host Microbe 2012, 12, 373–380. [Google Scholar] [CrossRef] [PubMed]
- Hauser, H.; Lopez, L.A.; Yang, S.J.; Oldenburg, J.E.; Exline, C.M.; Guatelli, J.C.; Cannon, P.M. HIV-1 Vpu and HIV-2 Env counteract BST-2/tetherin by sequestration in a perinuclear compartment. Retrovirology 2010, 7, 51. [Google Scholar] [CrossRef] [PubMed]
- Le Tortorec, A.; Neil, S.J. Antagonism to and intracellular sequestration of human tetherin by the human immunodeficiency virus type 2 envelope glycoprotein. J. Virol. 2009, 83, 11966–11978. [Google Scholar] [CrossRef] [PubMed]
- Schmokel, J.; Sauter, D.; Schindler, M.; Leendertz, F.H.; Bailes, E.; Dazza, M.C.; Saragosti, S.; Bibollet-Ruche, F.; Peeters, M.; Hahn, B.H.; et al. The presence of a Vpu gene and the lack of Nef-mediated downmodulation of t cell receptor-CD3 are not always linked in primate lentiviruses. J. Virol. 2011, 85, 742–752. [Google Scholar] [CrossRef] [PubMed]
- Serra-Moreno, R.; Zimmermann, K.; Stern, L.J.; Evans, D.T. Tetherin/BST-2 antagonism by Nef depends on a direct physical interaction between Nef and tetherin, and on clathrin-mediated endocytosis. PLoS Pathog. 2013, 9, e1003487. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, F.; Wilson, S.J.; Landford, W.C.; Virgen, B.; Gregory, D.; Johnson, M.C.; Munch, J.; Kirchhoff, F.; Bieniasz, P.D.; Hatziioannou, T. Nef proteins from simian immunodeficiency viruses are tetherin antagonists. Cell Host Microbe 2009, 6, 54–67. [Google Scholar] [CrossRef] [PubMed]
- Fukuma, A.; Abe, M.; Morikawa, Y.; Miyazawa, T.; Yasuda, J. Cloning and characterization of the antiviral activity of feline tetherin/BST-2. PLoS ONE 2011, 6, e18247. [Google Scholar] [CrossRef] [PubMed]
- Han, Z.; Lv, M.; Shi, Y.; Yu, J.; Niu, J.; Yu, X.F.; Zhang, W. Mutation of glycosylation sites in BST-2 leads to its accumulation at intracellular CD63-positive vesicles without affecting its antiviral activity against multivesicular body-targeted HIV-1 and hepatitis B virus. Viruses 2016, 8, 62. [Google Scholar] [CrossRef] [PubMed]
- Hu, S.; Pang, X.; Li, J.; Cen, S.; Jin, Q.; Guo, F. The role of the structural domains of human BST-2 in inhibiting the release of xenotropic murine leukemia virus-related virus. Biochem. Biophys. Res. Commun. 2012, 428, 17–23. [Google Scholar] [CrossRef] [PubMed]
- Takeda, E.; Nakagawa, S.; Nakaya, Y.; Tanaka, A.; Miyazawa, T.; Yasuda, J. Identification and functional analysis of three isoforms of bovine BST-2. PLoS ONE 2012, 7, e41483. [Google Scholar] [CrossRef] [PubMed]
- Tokarev, A.; Suarez, M.; Kwan, W.; Fitzpatrick, K.; Singh, R.; Guatelli, J. Stimulation of NF-κb activity by the HIV restriction factor BST2. J. Virol. 2013, 87, 2046–2057. [Google Scholar] [CrossRef] [PubMed]
- Wang, W.; Wang, J.; Qu, M.; Li, X.; Zhang, J.; Zhang, H.; Wu, J.; Yu, B.; Wu, H.; Kong, W.; et al. Viral restriction activity of feline BST2 is independent of its N-glycosylation and induction of NF-κb activation. PLoS ONE 2015, 10, e0138190. [Google Scholar] [CrossRef] [PubMed]
- Sakuma, T.; Noda, T.; Urata, S.; Kawaoka, Y.; Yasuda, J. Inhibition of Lassa and Marburg virus production by tetherin. J. Virol. 2009, 83, 2382–2385. [Google Scholar] [CrossRef] [PubMed]
- Xu, F.; Tan, J.; Liu, R.; Xu, D.; Li, Y.; Geng, Y.; Liang, C.; Qiao, W. Tetherin inhibits prototypic foamy virus release. Virol. J. 2011, 8, 198. [Google Scholar] [CrossRef] [PubMed]
- Taylor, J.K.; Coleman, C.M.; Postel, S.; Sisk, J.M.; Bernbaum, J.G.; Venkataraman, T.; Sundberg, E.J.; Frieman, M.B. Severe acute respiratory syndrome coronavirus ORF7a inhibits bone marrow stromal antigen 2 virion tethering through a novel mechanism of glycosylation interference. J. Virol. 2015, 89, 11820–11833. [Google Scholar] [CrossRef] [PubMed]
- Stanley, P.; Taniguchi, N.; Aebi, M. N-glycans. In Essentials of Glycobiology, 3rd ed.; Varki, A., Cummings, R.D., Esko, J.D., Stanley, P., Hart, G.W., Aebi, M., Darvill, A.G., Kinoshita, T., Packer, N.H., Prestegard, J.H., et al., Eds.; Cold Spring Harbor Laboratory Press: Cold Spring Harbor, NY, USA, 2015. [Google Scholar]
- Waheed, A.A.; MacDonald, S.; Khan, M.; Mounts, M.; Swiderski, M.; Xu, Y.; Ye, Y.; Freed, E.O. The Vpu-interacting protein SGTA regulates expression of a non-glycosylated tetherin species. Sci. Rep. 2016, 6, 24934. [Google Scholar] [CrossRef] [PubMed]
- Adachi, A.; Gendelman, H.E.; Koenig, S.; Folks, T.; Willey, R.; Rabson, A.; Martin, M.A. Production of acquired immunodeficiency syndrome-associated retrovirus in human and nonhuman cells transfected with an infectious molecular clone. J. Virol. 1986, 59, 284–291. [Google Scholar] [PubMed]
- Klimkait, T.; Strebel, K.; Hoggan, M.D.; Martin, M.A.; Orenstein, J.M. The human immunodeficiency virus type 1-specific protein Vpu is required for efficient virus maturation and release. J. Virol. 1990, 64, 621–629. [Google Scholar] [PubMed]
- Strebel, K.; Klimkait, T.; Martin, M.A. A novel gene of HIV-1, Vpu, and its 16-kilodalton product. Science 1988, 241, 1221–1223. [Google Scholar] [CrossRef] [PubMed]
- Waheed, A.A.; Ablan, S.D.; Mankowski, M.K.; Cummins, J.E.; Ptak, R.G.; Schaffner, C.P.; Freed, E.O. Inhibition of HIV-1 replication by amphotericin B methyl ester: Selection for resistant variants. J. Biol. Chem. 2006, 281, 28699–28711. [Google Scholar] [CrossRef] [PubMed]
- Takatsuki, A.; Arima, K.; Tamura, G. Tunicamycin, a new antibiotic. I. Isolation and characterization of tunicamycin. J. Antibiot. (Tokyo) 1971, 24, 215–223. [Google Scholar] [CrossRef] [PubMed]
- Zhou, T.; Dang, Y.; Zheng, Y.H. The mitochondrial translocator protein, TSPO, inhibits HIV-1 envelope glycoprotein biosynthesis via the endoplasmic reticulum-associated protein degradation pathway. J. Virol. 2014, 88, 3474–3484. [Google Scholar] [CrossRef] [PubMed]
- Elbein, A.D.; Tropea, J.E.; Mitchell, M.; Kaushal, G.P. Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I. J. Biol. Chem. 1990, 265, 15599–15605. [Google Scholar] [PubMed]
- Ono, A.; Orenstein, J.M.; Freed, E.O. Role of the gag matrix domain in targeting human immunodeficiency virus type 1 assembly. J. Virol. 2000, 74, 2855–2866. [Google Scholar] [CrossRef] [PubMed]
- Liang, Z.; Zhang, Y.; Song, J.; Zhang, H.; Zhang, S.; Li, Y.; Tan, J.; Qiao, W. The effect of bovine BST2a1 on the release and cell-to-cell transmission of retroviruses. Virol. J. 2017, 14, 173. [Google Scholar] [CrossRef] [PubMed]
- Wong, S.K.; Connole, M.; Sullivan, J.S.; Choe, H.; Carville, A.; Farzan, M. A new world primate deficient in tetherin-mediated restriction of human immunodeficiency virus type 1. J. Virol. 2009, 83, 8771–8780. [Google Scholar] [CrossRef] [PubMed]
© 2018 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Waheed, A.A.; Gitzen, A.; Swiderski, M.; Freed, E.O. High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release. Viruses 2018, 10, 26. https://doi.org/10.3390/v10010026
Waheed AA, Gitzen A, Swiderski M, Freed EO. High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release. Viruses. 2018; 10(1):26. https://doi.org/10.3390/v10010026
Chicago/Turabian StyleWaheed, Abdul A., Ariana Gitzen, Maya Swiderski, and Eric O. Freed. 2018. "High-Mannose But Not Complex-Type Glycosylation of Tetherin Is Required for Restriction of HIV-1 Release" Viruses 10, no. 1: 26. https://doi.org/10.3390/v10010026